TIE2gether · Next-generation therapeutics for vascular diseases

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

TIE2gether is a multidisciplinary research and training network addressing major unmet needs in vascular medicine.A wide range of vascular-related diseases—including chronic kidney disease, diabetic vasculopathy, sepsis, glaucoma and vascular malformations—affects millions and imposes a major societal and economic burden. Yet these conditions still lack effective, mechanism-based therapies. A unifying feature across these clinically distinct diseases is dysregulation of the TIE2 signalling cascade: hyperactivation drives vascular malformations while insufficient activity causes vascular leak, inflammation and organ dysfunction. Restoring balanced TIE2 signalling thus represents a major, largely unexplored therapeutic opportunity with relevance across both common and rare diseases.TIE2gether translates this opportunity into real-world benefit by training a new generation of scientists capable of bridging fundamental discovery with therapeutic innovation. The network brings together leading experts in vascular biology, organ-on-chip technologies, advanced disease modelling, chemical biology, protein engineering, and drug discovery. By centring around a single, highly druggable pathway, TIE2gether creates strong synergy and accelerates the transfer of mechanistic insight into validated therapeutic strategies evaluated in human-relevant systems.Fourteen Doctoral Candidates will gain cutting-edge competences in dissecting TIE2 signalling mechanisms, developing state-of-the-art disease models and designing and assessing next-generation therapeutics, including network-developed drug leads. Complemented by interdisciplinary, clinical and patient-facing training, they will acquire the innovation mindset, translational expertise and transferable skills needed across academia, industry and the biomedical sector. TIE2gether will deliver skilled researchers and novel therapeutic concepts to advance targeted treatments for vascular diseases with major societal impac

Original text from CORDIS.

Participants

• HELSINGIN YLIOPISTO · HelsinkiCoordinatorFinland
• BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION · KraainemBelgium
• BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG · ZwingenbergGermany
• CHARITE - UNIVERSITAETSMEDIZIN BERLIN · BerlinGermany
• CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL · Bruxelles / BrusselBelgium
• DE DUVE INSTITUTE AISBL · Bruxelles / BrusselBelgium
• EUROPEAN MOLECULAR BIOLOGY LABORATORY · HeidelbergGermany
• GENEVIA TECHNOLOGIES OY · TAMPEREFinland
• Night Science Institute LTD · New YorkCity levelUnited States
• Sang Biotech AB · UppsalaCity levelSweden
• UNIVERSIDADE CATOLICA PORTUGUESA · LISBOAPortugal
• UNIVERSITATSKLINIKUM BONN · BonnGermany
• UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEBelgium
• UNIVERSITY COLLEGE LONDON · LondonUnited Kingdom
• UPPSALA UNIVERSITET · UppsalaSweden

Links

• View on CORDIS
• DOI: 10.3030/101312820